Clinical trials: ifosfamide
Prognostic Cancer Model
Prognostic Significance of ctDNA in HL
Specific somatic mutations using ctDNA will be analyzed in predefined subgroups of cHL (e.g., age <60 and ≥ 60 years, EBV). These mutations will be correlated with response to the treatment in the first line, in the relapse…
- Trial name
- NCT06263530
- Where
- 5 sites in Czechia
- Volunteers
- 500 people
- Sponsor
- Interni hematologicka klinika FNKV
Penile Cancer
TIP Regimen Combined With Toripalimab Neoadjuvant Therapy for Locally Advanced Penile Cancer
Primary Objective: To evaluate the efficacy and safety of TIP (paclitaxel + ifosfamide + cisplatin) combined with Toripalimab as a neoadjuvant treatment in locally advanced penile cancer
- Trial name
- NCT06415318
- Testing
- Paclitaxel + Ifosfamide + Cisplatin & Toripalimab
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Sun Yat-sen University
Sarcoma
Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
Intensive chemotherapy is associated with significant thrombocytopenia, often requiring platelet transfusion to maintain platelet counts. This investigational drug has demonstrated the ability to increase platelet counts.
- Trial name
- NCT00038311
- Testing
- PN-152,243)/PN-196,444
- Where
- 6 sites in United States
- Volunteers
- 120 people
- Sponsor
- Pfizer
Ewing's Sarcoma
Phase II Pilot Study of Vincristine, Adriamycin, Actinomycin D, Ifosfamide Combination Chemotherapy in Ewing's Sarcoma
Phase II Pilot Study of Vincristine, Adriamycin, Actinomycin D, Ifosfamide combination chemotherapy in Ewing's Sarcoma
- Trial name
- NCT00541411
- Testing
- Vincristine, Actinomycin-D, Ifosfamide
- Volunteers
- 10 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Osteosarcoma
Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients
Trial evaluating the impact on efficacy of mifamurtide as add-on treatment to post-operative chemotherapy compared to post-operative chemotherapy alone in first-line treatment of patients with high-risk osteosarcoma (defined as…
- Trial name
- SARCOME13 (NCT03643133)
- Testing
- Mifamurtide, EI or M-API regimen depending on patient age
- Where
- 31 sites in France
- Volunteers
- 60 people
- Sponsor
- UNICANCER
Sarcoma
MRI Sarcoma Non Invasive Thermometry
RATIONALE: Hyperthermia therapy kills tumor cells by heating them to several degrees above body temperature. Using MRI to measure heat may help to determine the effectiveness of hyperthermia therapy.
- Trial name
- NCT00093509
- Testing
- doxorubicin hydrochloride, ifosfamide and mesna, hyperthermia treatment with an MRI Compatible Radiofrequency Extremity Hyperthermia Applicator
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mark Dewhirst
Penile Cancer
TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer
Primary Objective:To evaluate the efficacy and safety of TIP (paclitaxel + ifosfamide + cisplatin) combined with nimotuzumab \& triprilimab as neoadjuvant treatment in locally advanced penile cancer.
- Trial name
- NCT04475016
- Testing
- Albumin-Bound Paclitaxel, Ifosfamide, Cisplatin
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Sun Yat-sen University
Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
This phase II trial studies the effect of ascorbic acid and combination chemotherapy in treating patients with lymphoma that has come back (recurrent) or does not respond to therapy (refractory), clonal cytopenia of undetermined…
- Conditions
- Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma
- Trial name
- NCT03418038
- Testing
- Ascorbic Acid, Carboplatin, Cisplatin
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- Mayo Clinic
Diffuse Large B-Cell Lymphoma Refractory
Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCL
This study is to evaluate the efficacy and safety of Lenalidomide plus ICE in the treatment of Refractory and Relapsed DLBCL patients.
- Trial name
- NCT03367143
- Testing
- Lenalidomide, Ifosfamide, Carboplatin
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Ruijin Hospital
High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
This is an international multicenter, open-label, randomized phase III trial including three sequential randomizations to assess efficacy of induction and consolidation chemotherapies and radiotherapy for patients with high-risk…
- Trial name
- HR-NBL2 (NCT04221035)
- Testing
- Vincristine, Carboplatin, Etoposide
- Where
- 142 sites in Australia, Austria and 18 more
- Volunteers
- 800 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Sarcoma, Soft Tissue
Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients
Anlotinib is a multi-target receptor tyrosine kinase inhibitor. It can inhibit the angiogenesis related kinase, such as Vascular Endothelial Growth Factor Receptor (VEGFR), Fibroblast Growth Factor Receptor(FGFR)…
- Trial name
- ALTER-S005 (NCT03815474)
- Testing
- anlotinib
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Liaoning Cancer Hospital & Institute
Osteosarcoma, Neoadjuvant Therapy
Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma Patients
Given that osteosarcoma typically presents at an early age and predominantly affects pediatric and adolescent populations, early control of disease progression and the opportunity for complete tumor resection are particularly…
- Conditions
- Osteosarcoma, Neoadjuvant Therapy, Neoadjuvant Chemotherapy, PD-L1 Antibody
- Trial name
- NCT07142863
- Testing
- Envafolimab and neoadjuvant chemotherapy
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Non-Hodgkin Lymphoma
Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells
This phase II trial is studying how well giving rituximab; ifosfamide, carboplatin, and etoposide (ICE) combination chemotherapy; and filgrastim (G-CSF) together with plerixafor works in treating patients with non-Hodgkin…
- Trial name
- NCT01097057
- Testing
- Carboplatin, Etoposide, Filgrastim
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
Hodgkin's Lymphoma
Prognosis of Patients With Relapsed/Refractory Hodgkin Lymphoma Treated With IGEV Induction Therapy Before HDCT With AHSCT
This is a retrospective analysis of a homogeneous cohort of patients with relapsed/refractory HL that received IGEV scheme as induction therapy to HDCT and AHSCT for reassess the most common prognostic factors and try to identify…
- Trial name
- IIL-ProHLRec (NCT01478191)
- Where
- 40 sites in Italy
- Volunteers
- 495 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Retroperitoneal Sarcoma
Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma
The goal of this clinical trial is to explore the potential survival benefits of neoadjuvant chemotherapy combined with target treatments followed by radical surgery in patients with primary high-risk/grade retroperitoneal…
- Trial name
- NATARS (NCT05844813)
- Testing
- Doxorubicin+Ifosfamide+Anlotinib(AI+A), Radical Surgery
- Where
- 6 sites in China
- Volunteers
- 102 people
- Sponsor
- Peking University International Hospital
Relapsed/Refractory Large B-Cell Lymphoma
Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL
To evaluate the efficacy and safety of Linperlisib combined with standard immunochemotherapy in patients with R/R LBCL.
- Trial name
- NCT06489808
- Testing
- Linperlisib, Rituximab, Gemcitabine
- Where
- China
- Volunteers
- 89 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Metastatic Cancer, Sarcoma
Combination Chemotherapy, Radiation Therapy, and Sargramostim Before and After Surgery in Treating Patients With Soft Tissue Sarcoma That Can Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00652860
- Testing
- aerosol sargramostim, sargramostim, cisplatin
- Volunteers
- 39 people
- Sponsor
- Mayo Clinic
Soft Tissue Sarcoma
Therapeutic Response of Patients With Soft Tissue Sarcoma According to CHOI Criteria
Non-interventional study consisting of a population of patients who had received for soft tissue sarcoma by at least 2 courses of Yondelis® at a dose of 1.5 mg / m² / 3 weeks after failure or intolerance to doxorubicin /…
- Trial name
- ProAcTyon (NCT01650077)
- Where
- 6 sites in France
- Volunteers
- 134 people
- Sponsor
- Centre Oscar Lambret
Lymphoma
Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver…
- Trial name
- NCT00007865
- Testing
- rituximab, carboplatin, etoposide
- Where
- United States
- Sponsor
- University of Nebraska
Cancer
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill…
- Trial name
- NCT00002854
- Testing
- filgrastim, carboplatin, cisplatin
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- City of Hope Medical Center